XIAP and B-cell chronic lymphocytic leukemia: Although it is clear that CLL cells do not respond to cIAP specific SMAC mimetics such as Compound A [139], the BIR3 specific SMAC mimetic (i.e. XIAP targeted) Smac066 improves sensitivity in CLL cells [143].